Cingulate (CING) Competitors $4.34 -0.17 (-3.77%) Closing price 02/18/2025 03:58 PM EasternExtended Trading$4.53 +0.19 (+4.38%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CING vs. ALXO, LTRN, PDSB, IMMX, OTLK, VNRX, STTK, ATRA, RPTX, and CNTBShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include ALX Oncology (ALXO), Lantern Pharma (LTRN), PDS Biotechnology (PDSB), Immix Biopharma (IMMX), Outlook Therapeutics (OTLK), VolitionRx (VNRX), Shattuck Labs (STTK), Atara Biotherapeutics (ATRA), Repare Therapeutics (RPTX), and Connect Biopharma (CNTB). These companies are all part of the "pharmaceutical products" industry. Cingulate vs. ALX Oncology Lantern Pharma PDS Biotechnology Immix Biopharma Outlook Therapeutics VolitionRx Shattuck Labs Atara Biotherapeutics Repare Therapeutics Connect Biopharma ALX Oncology (NASDAQ:ALXO) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Does the MarketBeat Community believe in ALXO or CING? ALX Oncology received 42 more outperform votes than Cingulate when rated by MarketBeat users. However, 76.92% of users gave Cingulate an outperform vote while only 64.20% of users gave ALX Oncology an outperform vote. CompanyUnderperformOutperformALX OncologyOutperform Votes5264.20% Underperform Votes2935.80% CingulateOutperform Votes1076.92% Underperform Votes323.08% Does the media refer more to ALXO or CING? In the previous week, Cingulate had 2 more articles in the media than ALX Oncology. MarketBeat recorded 3 mentions for Cingulate and 1 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.51 beat Cingulate's score of 0.25 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cingulate 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, ALXO or CING? ALX Oncology has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500. Do institutionals & insiders believe in ALXO or CING? 98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 33.4% of ALX Oncology shares are owned by insiders. Comparatively, 17.1% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts recommend ALXO or CING? ALX Oncology presently has a consensus target price of $3.05, suggesting a potential upside of 157.38%. Cingulate has a consensus target price of $16.00, suggesting a potential upside of 268.66%. Given Cingulate's stronger consensus rating and higher possible upside, analysts clearly believe Cingulate is more favorable than ALX Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Cingulate 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Is ALXO or CING more profitable? ALX Oncology's return on equity of -93.02% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -93.02% -70.67% Cingulate N/A -570.20%-236.15% Which has stronger valuation & earnings, ALXO or CING? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$160.80M-$2.98-0.40CingulateN/AN/A-$23.53MN/AN/A SummaryALX Oncology beats Cingulate on 7 of the 13 factors compared between the two stocks. Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulatePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.49M$6.89B$5.81B$9.23BDividend YieldN/A2.89%5.25%3.99%P/E RatioN/A2.9216.7814.85Price / SalesN/A322.14469.7179.60Price / CashN/A73.0244.9938.25Price / Book-0.065.567.195.01Net Income-$23.53M$161.53M$3.20B$236.25M7 Day Performance-3.98%1.73%1.34%2.13%1 Month Performance-8.82%1.38%3.43%1.63%1 Year Performance274.14%-0.12%20.43%16.41% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate3.4576 of 5 stars$4.34-3.8%$16.00+268.7%+274.1%$14.49MN/A0.0020ALXOALX Oncology3.7054 of 5 stars$1.04-4.6%$3.05+193.3%-92.5%$54.85MN/A-0.3540LTRNLantern Pharma0.3998 of 5 stars$5.05-0.4%N/A+9.9%$54.44MN/A-2.8420Gap UpPDSBPDS Biotechnology1.3046 of 5 stars$1.45-0.7%$11.67+704.6%-73.7%$54.24MN/A-1.2520IMMXImmix Biopharma2.7171 of 5 stars$1.97-2.0%$7.00+255.3%-39.5%$54.20MN/A-2.329Gap DownHigh Trading VolumeOTLKOutlook Therapeutics2.0092 of 5 stars$1.69-1.2%$27.40+1,521.3%-81.1%$54.05MN/A-0.1920Earnings ReportAnalyst ForecastNews CoverageVNRXVolitionRx2.1686 of 5 stars$0.58-3.3%$3.75+546.6%-41.7%$53.75M$770,000.00-1.6180Analyst ForecastSTTKShattuck Labs3.703 of 5 stars$1.12-5.1%$8.67+673.8%-86.9%$53.47M$1.66M-0.73100News CoverageATRAAtara Biotherapeutics4.2182 of 5 stars$9.26-8.0%$17.75+91.7%-57.5%$53.34M$8.57M-0.36330RPTXRepare Therapeutics3.1396 of 5 stars$1.20flat$7.00+483.3%-80.7%$51.01M$51.13M-0.60180Upcoming EarningsNews CoverageCNTBConnect Biopharma3.7519 of 5 stars$0.92-6.6%$8.00+768.9%-30.0%$50.87MN/A0.00110 Related Companies and Tools Related Companies ALX Oncology Competitors Lantern Pharma Competitors PDS Biotechnology Competitors Immix Biopharma Competitors Outlook Therapeutics Competitors VolitionRx Competitors Shattuck Labs Competitors Atara Biotherapeutics Competitors Repare Therapeutics Competitors Connect Biopharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CING) was last updated on 2/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.